36 results
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
16 Apr 24
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
4:20pm
the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today reported … knowledge of the drug discovery industry to develop innovative therapies to treat chronic inflammatory diseases with the goal of improving the lives
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
12 Dec 23
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
6:10am
biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived … expertise in T cell biology and deep knowledge of the drug discovery industry to develop innovative therapies to treat chronic inflammatory diseases
6-K
EX-99.2
CNTB
Connect Biopharma Holdings Ltd
21 Nov 23
Exclusive License and Collaboration Agreement
6:13am
” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases … and Health Sciences in Washington, DC. “Moderate-severe AD is a chronic disease with high patient-burden. Multiple unmet needs remain with current
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies … Phase 2 trial for patients with chronic rhinosinusitis with nasal polyps in 2022, and higher product manufacturing costs incurred last year to enable
6-K
cvrk8z
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
6-K
EX-99.1
i8clz2zwdbj4hxa 1o
5 Jun 23
Current report (foreign)
4:28pm
6-K
EX-99.1
mad l1ke8x5zv
1 Jun 23
Current report (foreign)
4:24pm
6-K
EX-99.1
ah7er0
11 Apr 23
Connect Biopharma Reports Full Year 2022 Financial Results
5:00pm
6-K
i7ehovcfz
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
6-K
cixb8le6enx02
30 Aug 22
Current report (foreign)
4:01pm
F-3/A
rewkb35u1clr498hc8p0
17 Jun 22
Shelf registration (foreign) (amended)
5:19pm
F-3/A
2hfkakxgr
20 May 22
Shelf registration (foreign) (amended)
6:54pm
6-K
EX-99.1
8dm5mj9h og7ni
3 May 22
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis
4:36pm
F-3
vjuvl41lcu
15 Apr 22
Shelf registration (foreign)
5:27pm
6-K
EX-99.1
0lf18rz
31 Mar 22
Connect Biopharma Reports Full Year 2021 Financial Results
5:15pm
20-F
mw1fic spqou
31 Mar 22
Annual report (foreign)
4:33pm
6-K
EX-99.1
3li37 npp
16 Feb 22
Current report (foreign)
4:01pm
6-K
EX-99.1
lailu
5 Jan 22
Current report (foreign)
5:24pm